Simulations Plus

simulations-plus.com · Lancaster, United States of America

Simulations Plus develops and sells modeling and simulation software used by pharmaceutical, biotechnology, and chemical companies to support drug discovery, formulation, and regulatory submissions, along with related consulting and training services. Its platforms help scientists predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties and optimize clinical trial and dosing strategies. The company generates revenue through software licenses, SaaS subscriptions, and scientific consulting engagements.

Revenue
$50M - $250M
Employees
51 - 200
Founded
1996
Headquarters
Lancaster, United States of America

Simulations Plus customers on Arbolus

Total customers 8 6 current · 2 former
Reviews growth 7 new reviews since Apr 2026

Customers who reviewed Simulations Plus

Seniority of Simulations Plus customers

Most people who reviewed Simulations Plus hold Director roles (62%), followed by C-Suite (38%).

  • Director 62%
  • C-Suite 38%

Customers sample

Not specified Director NPS 7
Generalist Partner C-Suite NPS 7
Strategy Leader Director NPS 5 Undecided

Employer names and spend open in the full report, along with the other 5 customers.

What 8 Arbolus experts think of Simulations Plus

Overall sentiment: Positive

NPS distribution is 37.5% Promoters, 37.5% Passives, and 25% Detractors, with an average NPS of 7.75 and a score of 12.5. Renewal intent is mixed: 50% Yes, 0% No, 50% Not Sure. Most customers (62.5%) have used the product for more than one year. Key feedback themes include strong regulatory credibility, robust modeling features, and concerns about cost and workflow speed.

Everything 8 customers told us about Simulations Plus.

Employer names, spend, renewal intent and every written answer behind the numbers on this page.

Sentiment

12 Net Promoter Score, from 8 scored reviews
  • Promoters 3
  • Passives 3
  • Detractors 2

Praised

  • Trusted and Regulator-Accepted Tools
  • AI Integration and Automation

Criticised

  • Competitive Threat from Lower-Cost Solutions
  • Cost and Learning Curve

What Simulations Plus customers say

Trusted and Regulator-Accepted Tools

“I highly recommend Simulations Plus tools, especially the Lixoft suite, as they are among the best options for pharmacometrics and clinical pharmacology, with strong credibility among regulators and partners.”

Data Analyst · Health Care · 201 to 500 employees · North America

AI Integration and Automation

“A solution that integrated cleanly with AI assistance, automated repetitive steps, and lowered cost without compromising validation or regulatory acceptance would prompt me to switch.”

Data Analyst · Health Care · 201 to 500 employees · North America

Cost and Learning Curve

“Licensing for the Simulations Plus suite adds up, and setup and learning time can slow iteration, especially early in a program when questions change quickly.”

Data Analyst · Health Care · 201 to 500 employees · North America

Renewal intent

Plan to renew 50%
  • Will renew 2
  • Undecided 2
  • Not renewing 0

Plan to renew, by seniority

  • C-Suite 0% 1 answer
  • Director 67% 3 answers
  • 9.5/10 Average score from customers who will renew
  • 6.5/10 Average score from undecided customers

Report

Oct 2026 8 + 0

For people who use Simulations Plus

Do you use Simulations Plus at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 8 customers of Simulations Plus have already contributed

Takes a few minutes. Your identity stays anonymous.